Details for Patent: 9,119,848

« Back to Dashboard

Which drugs does patent 9,119,848 protect, and when does it expire?

Patent 9,119,848 protects LYBALVI and is included in one NDA.

This patent has twenty-three patent family members in nineteen countries.

Summary for Patent: 9,119,848

Title:	Morphinan derivatives for the treatment of drug overdose
Abstract:	The instant application relates to morphinan derivatives of Formula I with sustained effectiveness in treating drug toxicity and overdose:
Inventor(s):	Bernard Silverman, Fen-Ni Fu, Chengyun Guo
Assignee:	Alkermes Pharma Ireland Ltd
Application Number:	US12/903,462
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,119,848
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,119,848

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-001	May 28, 2021		RX	Yes	Yes	9,119,848			Y
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-002	May 28, 2021		RX	Yes	No	9,119,848			Y
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-003	May 28, 2021		RX	Yes	No	9,119,848			Y
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-004	May 28, 2021		RX	Yes	No	9,119,848			Y

International Family Members for US Patent 9,119,848

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010326676
Canada	2782529
Cyprus	1121646
Denmark	2506712